Skip to main content

注意 - ATTENTION

目前仅LUMINEX LTG部分的内容采用中文表达,所有其它内容依旧提供英文版本

Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Chinese.

Research, innovation and technological excellence

Goal 3
Goal 3

Ensure healthy lives and promote well-being for all at all ages

Goal 9
Goal 9

Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation

Goal 17
Goal 17

Strengthen the means of implementation and revitalize the global partnership for sustainable development

Diasorin’s commitment

A key factor in Diasorin’s success is the constant identification and selection of new products aimed at expanding the range offered to customers.
The Innovation Process ensures the organic involvement of all possible resources in new ideas for kits and tools, to ensure that excellence in innovation is achieved, even in new clinical areas.

The current Corporate Innovation Process also makes it possible to anticipate certain key analyses, to evaluate ex-ante risks and opportunities regarding investment and development times.

Actions taken

Nascita ed attuazione di un processo comune per lo Sviluppo Prodotto
Valutazione a 3 livelli di Stage & Gate

Process

From the need to guarantee an organic approach to new opportunities, a process shared by all Group companies was created, whereby Product Development work can only begin for projects that are profitable in terms of value and innovation.

Each project is evaluated through a 3-level Stage & Gate structure, in which the idea is analyzed according to 6 analytical axes:

  • Strategic Fit/Rationale
  • Market dimensions
  • Economics
  • Technical feasibility
  • Regulatory, Quality and Clinical Affairs
  • Project Management and risk assessment

Related disclosures:
GRI 3: Material topics